ACNEM in partnership with Biocelect, are hosting an information session with Dr Seth Toback MD, MMM – Vice President, Clinical Development-Coronavirus Vaccines Novavax INC on Novavax’s COVID-19 Vaccine Candidate NVX-CoV2373.
Please join ACNEM President Dr Mark Donohoe and Dr Seth Toback MD MMM for a presentation and Q&A session which will cover the following topics:
- How is it made?
- What is in it/excipients?
- Any potential reactions/contraindications?
- Data from about Phase 3 trial, including side effects
- Does it stop/reduce transmission?
- How effective and how long does efficacy last?
- How effective is it against the delta variant?
- When will it be available in Australia?
- Will it only be available as a booster?
You will also have the opportunity after the presentation to ask any questions you may have.
The session will held via Zoom, and you will be sent a link to join within the next day of you registering to join the meeting.
Dr Seth Toback MD, MMM
Clinical Development-Coronavirus Vaccines Novavax INC on Novavax’s COVID-19 Vaccine Candidate NVX-CoV2373.
Board certified and licensed physician with over 20 years experience in clinical practice and industry. Clinical Research/Medical Affairs and CRO experience within the respiratory, infectious diseases, in vitro diagnostics, allergy and vaccine therapeutic areas.
Currently working on the clinical development of a SARS-CoV-2 vaccine along with the team at Novavax. Lead clinician on the Phase 3 study being conducted in the United Kingdom. Building and leading the Medical Affairs department in charge of the medical launch of our COVID-19 vaccine and subsequent vaccines. Medical Affairs strategic lead for post-licensure studies, real-world evidence, publication planning and execution, scientific communications, medical information, investigator initiated studies and field medical science.
15th, October 2021 @ 12:00 pm - 1:00 pm